Depression in pregnancy is thought to affect up to one in five women globally in the late stages of pregnancy and shortly after birth.
It is characterised by low mood and feelings of hopelessness, and is brought on by a number of factors that can include life events such as bereavement, and changes in brain chemistry.
Researchers from Imperial College London found that depression or anxiety can reduce the enzyme in the placenta that breaks down the 'stress hormone' cortisol, possibly causing more foetal exposure to the hormone.
"Our review of available literature suggests that treating the depression itself is crucial in reducing the risk to the child, as well as for helping the mother," said Vivette Glover from Imperial College London.
"It shows targeting specific symptoms of depression by using cognitive behavioural therapy, for example, can be useful in reducing depression and therefore its effect on the child," said Glover.
"However, there is a substantial lack of research specific to women in poorer countries, where interventions such as cognitive behavioural therapy may not be available," she said.
The new review examined studies of mental health in children under five years old in low and middle income countries such as Bangladesh and Brazil.
Depression in mothers in low- and middle-income countries is common during and just after pregnancy, researchers said.
Women are more likely than in richer countries to experience intimate partner violence and have little social support.
The risk factors are often more intense and more common than in high-income countries.
These factors also intensify one another - for example, a malnourished mother or child may have too weak an immune system to fight an infection, exacerbating the mother's stress which then contributes to depression.
Maternal depression in these countries is also more likely to result in poor nutrition, increased substance use, inadequate antenatal care, pre-eclampsia, low birthweight, preterm delivery and suicide.
The study was published in The Lancet Psychiatry journal.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
